Immutep Limited

Our latest study at ZoomRx looks at the most exciting oncology pipeline assets according to healthcare professionals. From AbbVie's Teliso-V to Genentech's Tiragolumab, explore which treatments are capturing oncologists' attention and why. 📊 Dive into the full insights and see which innovations are set to transform cancer care. Read here: https://lnkd.in/gZeBJivc #oncology #cancertreatment #HCPinsights #pharmaresearch #ZoomRx #oncologists #cancercare #healthcare #healthcareresearch #pharma

Thank you, ausbiz for hosting Immutep Limited CEO Marc Voigt last week to talk about our recent progress in lung cancer, head and neck cancer and autoimmune disease. Watch the interview here: https://bit.ly/3ylnI44 #LAG3 #biotechnology #oncology

Thank you, Finance News Network for hosting CEO Marc Voigt to discuss Immutep Limited’s Phase III design for a trial in non-small cell lung cancer, our positive results in head and neck cancer, and clearance for a Phase I study in autoimmune diseases. Watch: https://bit.ly/3WKgMGW #LAG3 #biotechnology #oncology

Immutep Limited is pleased to provide an update on its activities for the quarter ended 30 June 2024 (Q4 FY24). Highlights include:   - Entered into third and most important clinical trial collaboration and supply agreement to date with MSD to evaluate efti in combination with KEYTRUDA® and chemotherapy for first-line non-small cell lung cancer in a pivotal Phase III trial - Continuing positive clinical data reported from efti - Positive regulatory feedback received from Spanish Agency for Medicines and Health Products Competent Authority regarding the upcoming TACTI-004 Phase III trial - Appointed Centre for Human Drug Research to conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to treat autoimmune diseases - Exclusive license agreement signed with Cardiff University / Prifysgol Caerdydd for development of an orally available, small molecule anti-LAG-3 therapy to treat cancer - A$100.2 million equity underwritten financing completed - Immutep cash runway extended to the end of calendar year 2026, with a strong cash totalling approximately A$181.8 million   Read the full ASX announcement here: https://bit.ly/4c6BJQZ   #LAG3 #immunotherapy #biotechnology #oncology

Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses Phase III design for a trial in non-small cell lung cancer, positive results in head and neck cancer, and clearance for a Phase I study in autoimmune diseases. https://lnkd.in/g7NS3dUX

Investigators of TACTI-004 plan to enroll approximately 750 patients regardless of PD-L1 expression in their assessment of the efti-based combination. https://lnkd.in/eKwttwaU #NSCLC #cancer #oncology

Clinical-stage biotechnology company Immutep Limited (ASX: IMM) has met with the US Food and Drug Administration (FDA) regarding the planned TACTI-004 Phase III trial of a treatment of first-line metastatic non-small cell lung cancer. https://hubs.li/Q02HB6yD0

📰 Member news ✅ Immutep Limited receives regulatory clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody 🌬️ Monash University research found early exposure to antibiotics can trigger asthma 🔎 Breakthrough Victoria high-performance computing and quantum chemistry revolutionises drug discovery 📈 WEHI (Walter and Eliza Hall Institute of Medical Research) collaborates on rapid drug test for improved patient care 🌟 Dr Liriye Kurtovic awarded Moderna Global Fellowship 2023 🫁 Immutep Limited successful meeting with FDA on Phase III Design in non-small cell lung cancer 🖋️ Alterity Therapeutics reports interim data from ATH434-202 Phase 2 trial ➡️ https://lnkd.in/gE-aB9tU

🔬 Insights from ASCO 2024! Dr Frederic Forget from Centre Hospitalier de l’Ardennes presents the AIPAC-003 study on eftilagimod alpha (efti) in breast cancer. This LAG-3 agonist aims to convert cold tumours into hot tumours, with the trial exploring the impact of increased dosing on survival outcomes. Discover the potential of efti in improving treatment responses. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #BreastCancer #OncologyInnovation #LAG3

#ASX #health #stocks: 💠 Immutep Limited ( $IMM ) gets FDA feedback 💠 Althea Group Holdings (ASX:AGH) enters into US joint venture 💠 Chimeric Therapeutics ( $CHM ) enrols first patient to Phase 1/2 trial